186 related articles for article (PubMed ID: 30917505)
1. Role of SIRT-3, p-mTOR and HIF-1α in Hepatocellular Carcinoma Patients Affected by Metabolic Dysfunctions and in Chronic Treatment with Metformin.
De Matteis S; Scarpi E; Granato AM; Vespasiani-Gentilucci U; La Barba G; Foschi FG; Bandini E; Ghetti M; Marisi G; Cravero P; Gramantieri L; Cucchetti A; Ercolani G; Santini D; Frassineti GL; Faloppi L; Scartozzi M; Cascinu S; Casadei-Gardini A
Int J Mol Sci; 2019 Mar; 20(6):. PubMed ID: 30917505
[TBL] [Abstract][Full Text] [Related]
2. Metformin and insulin impact on clinical outcome in patients with advanced hepatocellular carcinoma receiving sorafenib: Validation study and biological rationale.
Casadei Gardini A; Faloppi L; De Matteis S; Foschi FG; Silvestris N; Tovoli F; Palmieri V; Marisi G; Brunetti O; Vespasiani-Gentilucci U; Perrone G; Valgiusti M; Granato AM; Ercolani G; Negrini G; Tamburini E; Aprile G; Passardi A; Santini D; Cascinu S; Frassineti GL; Scartozzi M
Eur J Cancer; 2017 Nov; 86():106-114. PubMed ID: 28985579
[TBL] [Abstract][Full Text] [Related]
3. Metformin suppresses hypoxia-induced stabilization of HIF-1α through reprogramming of oxygen metabolism in hepatocellular carcinoma.
Zhou X; Chen J; Yi G; Deng M; Liu H; Liang M; Shi B; Fu X; Chen Y; Chen L; He Z; Wang J; Liu J
Oncotarget; 2016 Jan; 7(1):873-84. PubMed ID: 26621849
[TBL] [Abstract][Full Text] [Related]
4. Prognostic Significance of VEGF and HIF-1 α in Hepatocellular Carcinoma Patients Receiving Sorafenib Versus Metformin Sorafenib Combination.
El Shorbagy S; abuTaleb F; Labib HA; Ebian H; Harb OA; Mohammed MS; Rashied HA; Elbana KA; Haggag R
J Gastrointest Cancer; 2021 Mar; 52(1):269-279. PubMed ID: 32212089
[TBL] [Abstract][Full Text] [Related]
5. Hypoxia inducible factor 1α in hepatocellular carcinoma with cirrhosis: Association with prognosis.
Wang D; Zhang X; Lu Y; Wang X; Zhu L
Pathol Res Pract; 2018 Dec; 214(12):1987-1992. PubMed ID: 30274686
[TBL] [Abstract][Full Text] [Related]
6. Tubular injury in a rat model of type 2 diabetes is prevented by metformin: a possible role of HIF-1α expression and oxygen metabolism.
Takiyama Y; Harumi T; Watanabe J; Fujita Y; Honjo J; Shimizu N; Makino Y; Haneda M
Diabetes; 2011 Mar; 60(3):981-92. PubMed ID: 21282369
[TBL] [Abstract][Full Text] [Related]
7. Interplay Between SIRT-3, Metabolism and Its Tumor Suppressor Role in Hepatocellular Carcinoma.
De Matteis S; Granato AM; Napolitano R; Molinari C; Valgiusti M; Santini D; Foschi FG; Ercolani G; Vespasiani Gentilucci U; Faloppi L; Scartozzi M; Frassineti GL; Casadei Gardini A
Dig Dis Sci; 2017 Aug; 62(8):1872-1880. PubMed ID: 28527050
[TBL] [Abstract][Full Text] [Related]
8. Quantitative analysis of hepatic hypoxia-inducible factor-1alpha and its abnormal gene expression during the formation of hepatocellular carcinoma.
Yao DF; Jiang H; Yao M; Li YM; Gu WJ; Shen YC; Qiu LW; Wu W; Wu XH; Sai WL
Hepatobiliary Pancreat Dis Int; 2009 Aug; 8(4):407-13. PubMed ID: 19666411
[TBL] [Abstract][Full Text] [Related]
9. Orexin A affects HepG2 human hepatocellular carcinoma cells glucose metabolism via HIF-1α-dependent and -independent mechanism.
Wan X; Liu Y; Zhao Y; Sun X; Fan D; Guo L
PLoS One; 2017; 12(9):e0184213. PubMed ID: 28886081
[TBL] [Abstract][Full Text] [Related]
10. HIF-1α promoted vasculogenic mimicry formation in hepatocellular carcinoma through LOXL2 up-regulation in hypoxic tumor microenvironment.
Wang M; Zhao X; Zhu D; Liu T; Liang X; Liu F; Zhang Y; Dong X; Sun B
J Exp Clin Cancer Res; 2017 Apr; 36(1):60. PubMed ID: 28449718
[TBL] [Abstract][Full Text] [Related]
11. Metformin inhibits mTOR-HIF-1α axis and profibrogenic and inflammatory biomarkers in thioacetamide-induced hepatic tissue alterations.
Al-Hashem F; Al-Humayed S; Amin SN; Kamar SS; Mansy SS; Hassan S; Abdel-Salam LO; Ellatif MA; Alfaifi M; Haidara MA; Al-Ani B
J Cell Physiol; 2019 Jun; 234(6):9328-9337. PubMed ID: 30334569
[TBL] [Abstract][Full Text] [Related]
12. Expression of hypoxia-inducible factor 1alpha and vascular endothelial growth factor in hepatocellular carcinoma: Impact on neovascularization and survival.
Huang GW; Yang LY; Lu WQ
World J Gastroenterol; 2005 Mar; 11(11):1705-8. PubMed ID: 15786555
[TBL] [Abstract][Full Text] [Related]
13. Bufalin suppresses hepatocellular carcinoma invasion and metastasis by targeting HIF-1α via the PI3K/AKT/mTOR pathway.
Wang H; Zhang C; Xu L; Zang K; Ning Z; Jiang F; Chi H; Zhu X; Meng Z
Oncotarget; 2016 Apr; 7(15):20193-208. PubMed ID: 26958938
[TBL] [Abstract][Full Text] [Related]
14. Regulation of COX-2 expression and epithelial-to-mesenchymal transition by hypoxia-inducible factor-1α is associated with poor prognosis in hepatocellular carcinoma patients post TACE surgery.
Huang M; Wang L; Chen J; Bai M; Zhou C; Liu S; Lin Q
Int J Oncol; 2016 May; 48(5):2144-54. PubMed ID: 26984380
[TBL] [Abstract][Full Text] [Related]
15. Targeting AMPK, mTOR and β-Catenin by Combined Metformin and Aspirin Therapy in HCC: An Appraisal in Egyptian HCC Patients.
Abdelmonsif DA; Sultan AS; El-Hadidy WF; Abdallah DM
Mol Diagn Ther; 2018 Feb; 22(1):115-127. PubMed ID: 29094287
[TBL] [Abstract][Full Text] [Related]
16. Metformin and reduced risk of hepatocellular carcinoma in diabetic patients with chronic liver disease.
Donadon V; Balbi M; Mas MD; Casarin P; Zanette G
Liver Int; 2010 May; 30(5):750-8. PubMed ID: 20331505
[TBL] [Abstract][Full Text] [Related]
17. Hypoxia upregulates Rab11-family interacting protein 4 through HIF-1α to promote the metastasis of hepatocellular carcinoma.
Hu F; Deng X; Yang X; Jin H; Gu D; Lv X; Wang C; Zhang Y; Huo X; Shen Q; Luo Q; Zhao F; Ge T; Zhao F; Chu W; Shu H; Yao M; Fan J; Qin W
Oncogene; 2015 Dec; 34(49):6007-17. PubMed ID: 25745995
[TBL] [Abstract][Full Text] [Related]
18. Correlations between ADC values and molecular markers of Ki-67 and HIF-1α in hepatocellular carcinoma.
Huang Z; Xu X; Meng X; Hou Z; Liu F; Hua Q; Liu Q; Xiu J
Eur J Radiol; 2015 Dec; 84(12):2464-9. PubMed ID: 26456310
[TBL] [Abstract][Full Text] [Related]
19. Effects of metformin on clinical outcome in diabetic patients with advanced HCC receiving sorafenib.
Casadei Gardini A; Marisi G; Scarpi E; Scartozzi M; Faloppi L; Silvestris N; Masi G; Vivaldi C; Brunetti O; Tamberi S; Foschi FG; Tamburini E; Tenti E; Ricca Rosellini S; Ulivi P; Cascinu S; Nanni O; Frassineti GL
Expert Opin Pharmacother; 2015; 16(18):2719-25. PubMed ID: 26513009
[TBL] [Abstract][Full Text] [Related]
20. Hypoxia inducible factor in hepatocellular carcinoma: A therapeutic target.
Lin D; Wu J
World J Gastroenterol; 2015 Nov; 21(42):12171-8. PubMed ID: 26576101
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
